UBE2G1 Antibody

What is UBE2G1 and what is its function in the ubiquitination pathway?

UBE2G1 (Ubiquitin-conjugating enzyme E2 G1) is a member of the E2 ubiquitin-conjugating enzyme family that plays a crucial role in the ubiquitination process. This 19-20 kDa protein accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to target proteins. In vitro, UBE2G1 catalyzes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination, which are associated with different cellular outcomes . UBE2G1 is highly conserved across species, sharing 98-100% sequence identity with zebrafish, frog, rat, and mouse orthologs, indicating its fundamental importance in eukaryotic cellular processes .

The enzyme functions primarily in the cytoplasm where it transfers ubiquitin to target proteins, marking them for degradation by the proteasome. UBE2G1 helps eliminate damaged or misfolded proteins, thereby preventing the accumulation of potentially toxic proteins that could disrupt cellular functions . It is also involved in the degradation of muscle-specific proteins and mediates polyubiquitination of CYP3A4 .

What are the common applications of UBE2G1 antibodies in research?

UBE2G1 antibodies are utilized in multiple experimental approaches:

When performing Western blot analysis, UBE2G1 typically appears at approximately 20 kDa . For immunohistochemistry, antigen retrieval with TE buffer pH 9.0 is often recommended, though citrate buffer pH 6.0 may be used as an alternative .

How can I validate the specificity of a UBE2G1 antibody?

Comprehensive validation of UBE2G1 antibodies should employ multiple complementary approaches:

• CRISPR/Cas9 knockout validation: Generate UBE2G1 knockout cell lines using CRISPR/Cas9 gene editing. A specific antibody should show significantly reduced or absent signal in knockout cells compared to wild-type controls .

• Genetic rescue experiments: In UBE2G1 knockout cells, reintroduce wild-type UBE2G1 or an enzymatically-dead mutant (C90S). A specific antibody should detect the wild-type protein but may not recognize functionality of the mutant .

• Multi-antibody comparison: Use multiple antibodies targeting different epitopes of UBE2G1 and compare staining patterns across applications.

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide before application. Specific signals should be blocked or significantly reduced.

• Molecular weight verification: In Western blot applications, verify that the detected bands align with the predicted molecular weight of UBE2G1 (19-20 kDa) .

• Positive controls: Include recommended positive control samples such as HeLa, A549, HepG2, or HCT116 cell lysates .

What are the known interacting partners of UBE2G1 and how can these interactions be studied?

UBE2G1 interacts with several proteins within the ubiquitination pathway:

• E3 ligases: UBE2G1 cooperates with various E3 ligases that provide substrate specificity. For example, UBE2G1 works with CRL4(Cdt2) ubiquitin ligase to promote polyubiquitination and degradation of Cdt1 .

• NEDD8: Mass spectrometry studies identified NEDD8 as a key protein that directly interacts with UBE2G1, appearing in a highly connected network of potential UBE2G1 interacting proteins .

• UBE2D3: Research indicates that UBE2D3 works cooperatively with UBE2G1 in some ubiquitination pathways. UBE2D3 first attaches a single ubiquitin to target proteins before UBE2G1 assembles the polyubiquitin chain .

• CRBN complex: UBE2G1 interacts with the Cul4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase complex, particularly in the context of immunomodulatory drug mechanisms .

These interactions can be studied using various techniques:

• Co-immunoprecipitation (Co-IP): Pull down UBE2G1 and identify interacting partners by Western blot or mass spectrometry.

• GST pull-down assays: Use recombinant GST-UBE2G1 to capture interacting proteins from cell lysates, followed by SDS-PAGE separation and mass spectrometry analysis .

• Proximity-dependent labeling: BioID or TurboID fused to UBE2G1 can identify proteins in close proximity in living cells.

• Yeast two-hybrid screening: Identify novel protein-protein interactions.

• Fluorescence resonance energy transfer (FRET): Study real-time interactions in living cells.

How does UBE2G1 expression change under pathological conditions?

UBE2G1 expression patterns are altered in several disease states:

• Cancer: Reduced expression of UBE2G1 has been reported in medulloblastoma tumors, suggesting a potential tumor suppressor role .

• Multiple myeloma: Loss of UBE2G1 activity has been linked to clinical resistance to immunomodulatory drugs that utilize the CRL4CRBN E3 ligase to eliminate disease-driving proteins .

• Infectious diseases: In the large yellow croaker fish model, UBE2G1 expression is significantly upregulated following Pseudomonas plecoglossicida infection. The expression shows temporal dynamics, with levels gradually increasing in the liver and reaching maximum expression at 72 hours post-infection before declining .

• Neurodegenerative disorders: A key mutation in UBE2G1 has been identified in the brains of Alzheimer's disease patients, suggesting a potential role in neurodegeneration .

Immunohistochemical staining reveals that UBE2G1 protein expression can be significantly enhanced in various tissues (spleen, kidney, liver, and brain) following pathogen stimulation, indicating its active role in immune responses at both transcriptional and translational levels .

What methods are most effective for knocking down UBE2G1 expression to study its function?

Several approaches can be employed to modulate UBE2G1 expression:

For optimal experimental design, consider:

• Including appropriate controls (non-targeting gRNA, scrambled siRNA)

• Validating knockdown efficiency at both mRNA and protein levels

• Performing rescue experiments with wild-type UBE2G1 to confirm specificity

• Using multiple independent knockdown approaches to rule out off-target effects

What is the role of UBE2G1 in cancer research, particularly in multiple myeloma?

UBE2G1 plays a crucial role in the mechanism of action of immunomodulatory drugs (IMiDs) used to treat multiple myeloma. These findings have significant implications for understanding drug resistance mechanisms:

• Cereblon modulating agents: Drugs including lenalidomide, pomalidomide, and CC-220 repurpose the Cul4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase complex to target disease-driving proteins for degradation. UBE2G1 is critical for this process .

• Drug resistance mechanism: CRISPR knockout studies revealed that loss of UBE2G1 attenuates the degradation of endogenous IKZF1 (a key target in multiple myeloma treatment) by pomalidomide. This defect could be rescued by wild-type UBE2G1 but not by an enzymatically-dead mutant (C90S) .

• Cooperative ubiquitination pathway: UBE2G1 works in conjunction with UBE2D3 in a sequential process. UBE2D3 first links the disease-driving proteins with a single ubiquitin before UBE2G1 subsequently assembles a chain of ubiquitin proteins .

• Differential drug sensitivity: Myeloma cells lacking UBE2G1 showed resistance to certain drugs but remained sensitive to more potent drugs, suggesting that the success of some therapeutic agents depends on UBE2G1 activity .

These findings suggest that screening for UBE2G1 expression or activity could potentially identify patients likely to develop resistance to specific immunomodulatory drugs. Additionally, developing strategies to enhance UBE2G1 function might help overcome resistance in certain cancer types.

How can I design an experiment to investigate the role of UBE2G1 in a specific cellular pathway?

A comprehensive experimental approach should include:

• Expression analysis:

  • Assess baseline UBE2G1 expression in relevant cell types using qRT-PCR and Western blot

  • Examine subcellular localization using fluorescently-tagged UBE2G1 or immunofluorescence

  • Compare expression levels across normal and disease states

• Loss-of-function studies:

  • Generate UBE2G1 knockout cell lines using CRISPR/Cas9

  • Implement siRNA/shRNA knockdown for temporal control

  • Include both acute and chronic depletion models

  • Design rescue experiments with wild-type and mutant (C90S) UBE2G1

• Pathway analysis:

  • Examine changes in specific pathway components following UBE2G1 depletion

  • Use reporter assays to monitor pathway activity

  • Perform RNA-seq and proteomics to identify global changes

  • Conduct ubiquitinome analysis using K-ε-GG enrichment mass spectrometry

• Interactome mapping:

  • Perform immunoprecipitation followed by mass spectrometry to identify interacting partners

  • Use GST pull-down assays as demonstrated in large yellow croaker studies

  • Validate key interactions using proximity ligation assays

  • Consider pathway-specific interactome analysis under relevant stimulation conditions

• Functional assays:

  • Assess effects on protein degradation rates for known or suspected substrates

  • Examine cell proliferation, migration, or differentiation in UBE2G1-deficient cells

  • Analyze response to relevant stress conditions or pathway activators

  • Implement time-course experiments to capture dynamic changes (as seen in infection models where UBE2G1 expression peaks at specific time points)

• In vivo validation:

  • Generate tissue-specific UBE2G1 knockout animal models

  • Examine physiological consequences in relevant disease models

  • Analyze tissue samples from patients with disorders affecting the pathway of interest

What are the technical challenges in studying UBE2G1 ubiquitination activity in vitro?

In vitro analysis of UBE2G1 enzymatic activity presents several technical challenges:

• Maintaining enzyme integrity:

  • The active site cysteine (C90) is sensitive to oxidation

  • Storage conditions significantly impact activity (requiring DTT and glycerol)

  • Enzyme preparation methods may affect catalytic efficiency

• Reconstituting complete ubiquitination cascades:

  • Requires coordinated activity of E1, UBE2G1, and appropriate E3 ligases

  • Buffer conditions must support all enzymes simultaneously

  • Identifying physiologically relevant E3 partners can be challenging

• Chain type specificity:

  • UBE2G1 can catalyze both 'Lys-48'- and 'Lys-63'-linked polyubiquitination in vitro

  • Distinguishing between chain types requires specialized antibodies or mass spectrometry

  • Controlling chain type formation may require additional factors

• Sequential E2 cooperation:

  • As demonstrated with UBE2D3 and UBE2G1, some ubiquitination pathways involve multiple E2s acting sequentially

  • Reconstituting this cooperative activity requires careful enzyme titration and timing

• Substrate specificity:

  • Identifying bona fide substrates is challenging

  • In vitro systems may not recapitulate cellular context that influences substrate selection

  • Substrate preparation (including post-translational modifications) may affect recognition

• Activity assays:

  • Traditional enzyme assays may not be applicable to multi-step ubiquitination reactions

  • Developing quantitative readouts with sufficient sensitivity and dynamic range

  • Discriminating between ubiquitin chain initiation and elongation activities

Several approaches can address these challenges:

• Use recombinant His-tagged UBE2G1 with verified enzymatic activity (11 pmol/min/μg)

• Include appropriate controls (enzymatically-dead C90S mutant)

• Apply multiple assay formats to verify activity (gel-based assays, fluorescence-based assays)

• Implement time-course experiments to capture the dynamics of ubiquitination